Uncategorized
NuVasive Ups Bet on Orthobiologics
Alex Lukianov, NuVasive Chair and CEO, is hoping to fill a gap in the $1 billion orthobiologics market between BMPs (bone morphogenic proteins) and commodity synthetic and allograft bone extenders.